We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Protagen Successfully Closes New Financing Round


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Protagen Successfully Closes New Financing Round"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

PROTAGEN AG today announced the closing of a new financing round.  In this round, QIAGEN N.V., joins existing investors MIG Fonds, Munich, NRW.BANK, Düsseldorf, and Protagen Management.
 
This is the first closing of a financing round with a total volume of € 10 Mio. The second closing with additional new investors is planned for the third quarter of 2015.

This latest financing round demonstrates the confidence of new and existing investors in Protagen, based upon reaching significant milestones, such as the Pharma collaboration with Pfizer Inc. and the mid 2014 launch of the first research use ADx Multilisa® SSc assay.
 
“The successful first closing of this round marks a significant milestone in our development and growth,” said Dr. Stefan Müllner, CEO, Protagen AG. “The financial investment will enable Protagen to complete and commercialize its current IVD development programs in Rheumatoid Arthritis, Systemic Lupus, and Systemic Sclerosis. In addition, it will strengthen our position for furthering our partnerships with Pharma and Biotech companies in one of the most attractive drug development areas.”

Advertisement